BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 1, 2024
See today's BioWorld
Home
» Roche, Genentech Finally Agree to Acquisition at $95 per Share
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Roche, Genentech Finally Agree to Acquisition at $95 per Share
March 13, 2009
By
Jennifer Boggs
No Comments
The acquisition everyone has expected since Roche Holdings AG first made an offer eight months ago finally looks to happen, as Genentech Inc. agreed to a takeover by its Swiss pharma partner in a deal valued at about $46.8 billion. (BioWorld Today)
BioWorld